Stephen Rosenberg, MD, MS
Dr. Stephen Rosenberg is an Assistant Member in the Section of Thoracic Oncology of the Moffitt Cancer Center Department of Radiation Oncology. His clinical focus is the treatment of patients with thoracic malignancies, including lung cancer and malignant pleural mesothelioma, combining radiation with immunomodulatory drugs and targeted therapies to improve patient outcomes.[1]
Education and Career
Dr. Rosenberg graduated from Brown University with a Bachelor of Science degree in Biology. He earned both a Master of Science degree in Clinical and Translational Research and his medical degree at Rutgers University and while there was named a Howard Hughes Medical Institute Research Fellow. He completed his medical internship at Memorial Sloan Kettering Cancer Center in New York City, where he was named the Suzanne Munson Intern of the Year, and then completed his residency in radiation oncology at the University of Wisconsin, where he also served as Chief Resident.[1]
Professional Memberships
Dr. Rosenberg is an active member of several professional associations, including:[1]
- American Society for Radiation Oncology – ASTRO
- American Society of Clinical Oncology – ASCO
- Radiological Society of North America – RSNA
Research
Dr. Rosenberg is actively involved in research with a special focus on MRI-guided radiation. Much of his study concentrates on utilizing radiomics and genomics. His work is part of the FORT (Future of Radiation Therapy) Departmental research program aimed at personalizing radiation therapy using novel approaches to improve local control of tumors and decrease radiation therapy’s side effects for patients.[1]
Dr. Rosenberg’s recent publications include:[1]
- Bryant JM, Weygand J, Keit E, Cruz-Chamorro R, Sandoval ML, Oraiqat IM, Andreozzi J, Redler G, Latifi K, Feygelman V, Rosenberg SA. Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions. Cancers (Basel). 2023 Mar.15(7). Pubmedid: 37046741. Pmcid: PMC10093051.
- Chuong MD, Clark MA, Henke LE, Kishan AU, Portelance L, Parikh PJ, Bassetti MF, Nagar H, Rosenberg SA, Mehta MP, Refaat T, Rineer JM, Smith A, Seung S, Zaki BI, Fuss M, Mak RH. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States – Understanding the transition to adaptive, ultra-hypofractionated treatments. Clin Transl Radiat Oncol. 2023 Jan.38:161-168. Pubmedid: 36466748. Pmcid: PMC9712826.
- Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jan. Pubmedid: 36657497.
- Oliver DE, Laborde JM, Singh DP, Milano MT, Videtic GM, Williams GR, Lariviere MJ, Chan JW, Peters GW, Decker RH, Samson P, Robinson CG, Breen WG, Owen D, Tian S, Higgins KA, Almeldin D, Jabbour SK, Wang F, Grass GD, Perez BA, Dilling TJ, Strosberg J, Rosenberg SA. Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience. Int J Radiat Oncol Biol Phys. 2023 Jan. Pubmedid: 36708788.
- Bryant JM, Sim AJ, Feygelman V, Latifi K, Rosenberg SA. Adaptive hypofractionated and stereotactic body radiotherapy for lung tumors with real-time MRI guidance. Front Oncol. 2023 Jan.13:1061854. Pubmedid: 36776319. Pmcid: PMC9911810.
- Song EY, Chuang J, Frakes JM, Dilling T, Quinn JF, Rosenberg S, Johnstone P, Harrison L, Hoffe SE. Developing a Dedicated Leadership Curriculum for Radiation Oncology Residents. J Cancer Educ. 2022 Oct.37(5):1446-1453. Pubmedid: 33619686.
- Graham JA, Redler G, Delozier KB, Yu HM, Oliver DE, Rosenberg SA. Dosimetric feasibility of hippocampal avoidance whole brain radiotherapy with an MRI-guided linear accelerator. J Appl Clin Med Phys. 2022 Jun.23(6):e13587. Pubmedid: 35344266. Pmcid: PMC9195042.
- Kim H, Lee P, Tree AC, Chuong MD, Raldow AC, Kishan AU, Fuller CD, Rosenberg SA, Hall WA, Chie EK, Portelance L. Adaptive Radiation Therapy Physician Guidelines: Recommendations From an Expert Users’ Panel. Pract Radiat Oncol. 2022 Jun.12(5):e355-e362. Pubmedid: 35644469.
